Influence of Radiotherapy and Tamoxifen on Contralateral Cancer Risk in Women with Hereditary Breast Cancer
Abstract
Women with breast cancer arising as a consequence of germline mutations in BRCA1 or BRCA2 are at significant risk of contralateral breast cancer (CBC). Examination of factors influencing contralateral risk will provide insight into prevention strategies for unaffected women with BRCA mutations. A combined analysis performed with the JGH indicates tamoxifen may reduce CBC risk by 53% (attached). To evaluate CBC risk factors, the funded study is assessing the impact of tamoxifen and radiotherapy on CBC risk. In the present funding period, in accordance with the Statement of Work, continued review of clinical records was performed, with identification of pathology blocks that will be cut to provide the samples for genotyping. Medical records from 1990 and 1991 were not reliably retrievable, leading us to expand the cohort eligibility dates to 199E. As of this report, we have reviewed 692 records in this interval, of whom 453 are eligible and for whom data has been entered. Data cleaning is in process and acquisition of tissue samples will begin shortly, followed by genotyping after anonymization. Combining these data with our original cohort of 329 cancers in 305 patients (JNCI 1999), we will have achieved 78% of our accrual goal of 1000 cases.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA422981
Entities
People
- Mark E. Robson
Organizations
- Memorial Sloan Kettering Cancer Center